Quick Answer
60 DEGREES PHARMACEUTICALS, INC. reported Diluted EPS of $11.73 per share (loss) for fiscal year 2025.
60 DEGREES PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$11.73 | +84.2% |
| 2024 | -$74.17 | -25.3% |
| 2023 | -$59.18 | -2167.4% |
| 2022 | -$2.61 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.66 | +77.4% | +47.2% |
| June 30, 2025 | -$1.25 | +94.1% | +19.9% |
| March 31, 2025 | -$1.56 | -185.2% | +46.6% |
| September 30, 2024 | -$2.92 | -132.0% | +86.2% |
| June 30, 2024 | -$21.12 | -25.4% | -1254.1% |
| March 31, 2024 | $1.83 | +261.9% | -80.0% |
| September 30, 2023 | $9.13 | +1596.7% | +154.2% |
| June 30, 2023 | -$16.84 | -1654.2% | -1390.3% |
- 60 DEGREES PHARMACEUTICALS, INC. showed an increase of +84.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, 60 DEGREES PHARMACEUTICALS, INC.’s diluted eps has declined by 349.4% (from $2.61 per share (loss) to $11.73 per share (loss)).
- The most recent figure is from 60 DEGREES PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: